
    
      open label, randomized, two-treatment, three-period, three-sequence, partial replicate oral
      bioequivalence study of Lansoprazole 30 mg DR Capsules of Dr.Reddy's Laboratories Limited,
      India comparing with that of PREVACIDÂ® (containing Lansoprazole) 30 mg DR Capsules of TAP
      Pharmaceuticals Inc. USA, in healthy, adult, human subjects under fasting conditions. 48
      healthy, adult, human subjects were enrolled in the study and 42 subjects were completed the
      study.
    
  